{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:30:34Z","timestamp":1793449834239,"version":"4.5.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Left ventricular hypertrophy (LVH) is a hallmark of uremic cardiomyopathy and a strong predictor of adverse outcomes in chronic kidney disease (CKD). Conventional biomarkers often fail to capture the full spectrum of risk, highlighting the need for novel predictors. Fibroblast growth factor\u201123 (FGF\u201123) has been implicated in pathological cardiac remodeling through FGFR4\u2011dependent signaling pathways. This study aimed to evaluate the diagnostic utility of circulating FGF\u201123 for cardiac remodeling, particularly Left ventricular hypertrophy, in non\u2011dialysis CKD patients. A cross\u2011sectional observational study was conducted between October 2024 and April 2025 in Thi\u2011Qar, Iraq. Participants included 89 patients with CKD stage 3 to 5, 40 patients with heart failure, and 37 healthy controls. Demographic, clinical, biochemical, and echocardiographic data were collected. Serum FGF\u201123 was measured using enzyme-linked immunosorbent assay. Associations with cardiac remodeling were assessed using logistic regression models with sequential adjustments. Diagnostic performance was evaluated by receiver operating characteristic curve analysis. Serum FGF\u201123 was significantly higher in CKD and heart failure groups compared to controls. Among CKD patients, FGF\u201123 levels were elevated in those with cardiac remodeling (164.9 vs 133.4 pg\/mL). Receiver operating characteristic analysis yielded an area under the curve of 0.723, with an optimal cutoff of\u2005&gt;164.8 pg\/mL (sensitivity, 50.9%; specificity, 96.7%). Multivariate regression confirmed FGF-23 as an independent risk factor for remodeling across all adjustment models (odds ratio range, 1.021\u20131.039;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.01). Circulating FGF-23 is independently associated with cardiac remodeling in non-dialysis CKD patients. Its high specificity suggests potential utility as a biomarker for cardiovascular risk stratification, complementing traditional measures.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049451","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:01:05Z","timestamp":1783720865000},"page":"e49451","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Cardiac remodeling in CKD: Diagnostic utility of circulating fibroblast growth factor\u201123"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1118-7941","authenticated-orcid":false,"given":"Karrar Mohammed","family":"Abbas","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7038-8416","authenticated-orcid":false,"given":"Mohammed Mahmood","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3480-8811","authenticated-orcid":false,"given":"Muhammad A.","family":"Hamas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Al Nasiriya Teaching Hospital, Republic of Iraq, Ministry of Health, Al Nasiriya, Iraq."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease \u2013 a systematic review and meta-analysis.","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3390\/biom13050773","article-title":"Cardiac imaging biomarkers in chronic kidney disease.","volume":"13","author":"Valbuena-L\u00f3pez","year":"2023","journal-title":"Biomolecules"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/ndt\/gfz254","article-title":"Prognostic values of left ventricular mass index in chronic kidney disease patients.","volume":"36","author":"Tripepi","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.5958\/0976-5506.2019.04040.3","article-title":"Dosing of erythropoietin stimulating agents in patients on hemodialysis: a single-center study.","volume":"10","author":"Abed","year":"2019","journal-title":"Ind J Publ Health Res Develop"},{"issue":"Supplement_2","key":"R5-20261001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurheartj\/ehad655.2754","article-title":"Impact of early stages of CKD with and without proteinuria on cardiac remodelling in UK Biobank cohort.","volume":"44","author":"Naderi","year":"2023","journal-title":"Eur Heart J"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4236\/ojneph.2020.103017","article-title":"Cardiovascular disease burden in patients with non-dialysis dependent chronic kidney disease in cameroon: case of the douala general hospital.","volume":"10","author":"Halle","year":"2020","journal-title":"OJNeph"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43162-025-00435-8","article-title":"Correlation linking fibroblast growth factor 23 in circulation (FGF-23) and serum aldosterone levels in different stages of chronic kidney disease.","volume":"37","author":"Dohuim","year":"2025","journal-title":"Egypt J Intern Med"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy.","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/jbmr.170","article-title":"FGF-23: More than a regulator of renal phosphate handling?","volume":"25","author":"J\u00fcppner","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12882-021-02528-2","article-title":"Longitudinal change in c-terminal fibroblast growth factor 23 and outcomes in patients with advanced chronic kidney disease.","volume":"22","author":"Alderson","year":"2021","journal-title":"BMC Nephrol"},{"issue":"Supplement_1","key":"R12-20261001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ndt\/gfad063d_4051","article-title":"#4051 FGF-23 In chronic kidney disease: correlation with bone and cardiovascular parameters \u2013 a preliminary study.","volume":"38","author":"Machado","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/s41598-017-02068-6","article-title":"FGF23\/FGFR4-mediated left ventricular hypertrophy is reversible.","volume":"7","author":"Grabner","year":"2017","journal-title":"Sci Rep"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/jcdd11100320","article-title":"FGFR4 is required for concentric growth of cardiac myocytes during physiologic cardiac hypertrophy.","volume":"11","author":"Campos","year":"2024","journal-title":"J Cardiovasc Dev Dis"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"1059179","DOI":"10.3389\/fendo.2023.1059179","article-title":"Direct and indirect effects of fibroblast growth factor 23 on the heart.","volume":"14","author":"Nakano","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R16-20261001","first-page":"e322","article-title":"The correlation between serum fibroblast growth factor-23 levels and left ventricular hypertrophy in chronic kidney disease patients.","volume":"13","author":"Karim","year":"2023","journal-title":"J Renal Inj Prev"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of lupus nephritis.","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"R18-20261001","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart association task force on clinical practice guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"R21-20261001","first-page":"S20","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2024.","volume":"47","author":"ElSayed","year":"2024","journal-title":"Diabetes Care"},{"key":"R23-20261001","first-page":"1","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD).","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"235","DOI":"10.21608\/jbaar.2024.361942","article-title":"linkage between the duration of diabetes mellitus type-2 with the biochemical measurements and the extent of chronic complications.","volume":"10","author":"Abdulkareem","year":"2024","journal-title":"J Biosci Appl Res"},{"key":"R25-20261001","first-page":"2157","article-title":"Evaluation of insulin resistance according to the obesity grades in Iraqi non-diabetic adults.","volume":"20","author":"Abdul Kareem","year":"2020","journal-title":"Biochem Cellular Arch"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.echo.2025.06.001","article-title":"Guidelines for the standardization of adult echocardiography reporting: recommendations from the American society of echocardiography.","volume":"38","author":"Taub","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"key":"R27-20261001","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"118","DOI":"10.22159\/ajpcr.2018.v11i10.27059","article-title":"Assessment of cardiac function in patients with chronic myeloid leukemia treated with imatinib at the national center of hematology.","volume":"11","author":"Taher","year":"2018","journal-title":"Asian J Pharm Clin Res"},{"key":"R29-20261001","doi-asserted-by":"crossref","first-page":"674","DOI":"10.5958\/0976-5506.2019.01354.8","article-title":"The role of myocardial performance index in assessment of left ventricular function in patients with valvular mitral regurgitation.","volume":"10","author":"Jabbar","year":"2019","journal-title":"Ind J Publ Health Res Develop"},{"key":"R30-20261001","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/jcdd12080290","article-title":"Fibroblast growth factor 23 is a strong predictor of adverse events after left ventricular assist device implantation.","volume":"12","author":"Yared","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"key":"R31-20261001","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nefroe.2021.08.004","article-title":"FGF23: from academic nephrology to personalized patients\u2019 care.","volume":"41","author":"Gonz\u00e1lez-Casaus","year":"2021","journal-title":"Nefrologia (Engl Ed)"},{"key":"R32-20261001","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40256-024-00688-8","article-title":"Vitamin D\u2013parathyroid hormone\u2013fibroblast growth factor 23 axis and cardiac remodeling.","volume":"25","author":"Deng","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"R33-20261001","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.3390\/ijms25094875","article-title":"Non-classical effects of FGF23: molecular and clinical features.","volume":"25","author":"Mart\u00ednez-Heredia","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R34-20261001","first-page":"1","article-title":"A review of the role of fibroblast growth factor 23 in phosphate homeostasis and the pathophysiology of mineral bone disorder associated with chronic kidney disease.","volume":"1","author":"Elliott","year":"2023","journal-title":"Int Renal Interest Soc"},{"key":"R35-20261001","doi-asserted-by":"crossref","first-page":"e10446","DOI":"10.34172\/npj.2022.10446","article-title":"Correlation of glomerular filtration rate and fibroblast growth factor-23 levels in chronic kidney disease; sub analysis chronic kidney disease\u2013mineral and bone disorder study.","volume":"13","author":"Tahir","year":"2022","journal-title":"J Nephropharmacol"},{"key":"R36-20261001","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s44324-025-00087-w","article-title":"Deletion of cardiac fibroblast growth factor-23 beneficially impacts myocardial energy metabolism in left ventricular hypertrophy.","volume":"3","author":"Latic","year":"2025","journal-title":"NPJ Metab Health Dis"},{"key":"R37-20261001","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ejhf.1632","article-title":"Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.","volume":"22","author":"Nauta","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R38-20261001","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.3390\/jcm13175313","article-title":"Left ventricular diastolic dysfunction across levels of kidney function: a cross-sectional study based on routine clinical practice data.","volume":"13","author":"Porras","year":"2024","journal-title":"JCM"},{"key":"R39-20261001","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/ckj\/sfad177","article-title":"Diastolic function in chronic kidney disease.","volume":"16","author":"de Simone","year":"2023","journal-title":"Clin Kidney J"},{"key":"R40-20261001","doi-asserted-by":"crossref","first-page":"848692","DOI":"10.3389\/fcvm.2022.848692","article-title":"Association between left ventricular geometry and renal outcomes in patients with chronic kidney disease: findings from Korean cohort study for outcomes in patients with chronic kidney disease study.","volume":"9","author":"Suh","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R41-20261001","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/ckj\/sfad144","article-title":"The open system of FGF-23 at the crossroad between additional P-lowering therapy, anemia and inflammation: how to deal with the intact and the C-terminal assays?","volume":"16","author":"Magagnoli","year":"2023","journal-title":"Clin Kidney J"},{"key":"R42-20261001","first-page":"334","article-title":"Serum FGF-23 and vitamin D deficiency as predictors of metabolic syndrome in chronic kidney disease.","volume":"14","author":"Shah","year":"2025","journal-title":"Pak J Med Dentistry"},{"key":"R43-20261001","first-page":"1","article-title":"Correlation of FGF 23 with other biomarkers and left ventricular hypertrophy in patients with end-stage renal disease on hemodialysis: a cross sectional study.","volume":"6","author":"Yusubov","year":"2025","journal-title":"J Comm Med and Pub Health Rep"},{"key":"R44-20261001","doi-asserted-by":"crossref","first-page":"e027609","DOI":"10.1161\/JAHA.122.027609","article-title":"Left ventricular diastolic dysfunction and progression of chronic kidney disease: analysis of KNOW\u2010CKD data.","volume":"12","author":"Kang","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R45-20261001","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s12872-023-03441-2","article-title":"Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction.","volume":"23","author":"Vergaro","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"R46-20261001","first-page":"100747","article-title":"FGF-23, left ventricular hypertrophy, and mortality in patients with CKD: a revisit with mediation analysis.","volume":"3","author":"Hidaka","year":"2024","journal-title":"JACC"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:00:31Z","timestamp":1790881231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":45,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049451","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"2025-11-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}